Emerald Advisers, LLC Immuno Gen, Inc. Transaction History

Emerald Advisers, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$12.46 - $29.95 $826,409 - $1.99 Million	-66,325 Reduced 3.66%	1,744,981 $51.7 Million
Q3 2023 Oct 26, 2023	BUY	$14.09 - $19.87 $11.7 Million - $16.4 Million	827,609 Added 84.13%	1,811,306 $28.7 Million
Q2 2023 Jul 25, 2023	BUY	$3.75 - $20.05 $3.69 Million - $19.7 Million	983,697 New	983,697 $18.6 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.